PlainRecalls
FDA Drug Moderate Class II Terminated

Lyrica CR (pregabalin) extended release tablets, 330 mg, 30-count bottles, Rx only, Distributed by Parke-Davis Division of Pfizer Inc., NY, NY 10017, NDC 0071-1029-01

Reported: October 6, 2021 Initiated: August 23, 2021 #D-0851-2021

Product Description

Lyrica CR (pregabalin) extended release tablets, 330 mg, 30-count bottles, Rx only, Distributed by Parke-Davis Division of Pfizer Inc., NY, NY 10017, NDC 0071-1029-01

Reason for Recall

Failed Dissolution Specifications

Details

Recalling Firm
Viatris
Units Affected
9,515 bottles
Distribution
Nationwide within the United States
Location
Morgantown, WV

Frequently Asked Questions

What product was recalled?
Lyrica CR (pregabalin) extended release tablets, 330 mg, 30-count bottles, Rx only, Distributed by Parke-Davis Division of Pfizer Inc., NY, NY 10017, NDC 0071-1029-01. Recalled by Viatris. Units affected: 9,515 bottles.
Why was this product recalled?
Failed Dissolution Specifications
Which agency issued this recall?
This recall was issued by the FDA Drug on October 6, 2021. Severity: Moderate. Recall number: D-0851-2021.